Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to acquire Nightstar Therapeutics, a UK-based clinical-stage gene ... Read More
Spark Therapeutics’ Luxturna nears FDA approval for gene therapy treating inherited blindness
In a significant development in gene therapy, Spark Therapeutics' Luxturna (voretigene neparvovec) is on the verge of receiving FDA approval for treating blindness caused by ... Read More